{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:21:24Z","timestamp":1774437684412,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.ijcard.2016.04.127","type":"journal-article","created":{"date-parts":[[2016,4,22]],"date-time":"2016-04-22T16:38:26Z","timestamp":1461343106000},"page":"46-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval"],"prefix":"10.1016","volume":"216","author":[{"given":"Faiez","family":"Zannad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy Gattis","family":"Stough","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murray","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria de los Angeles","family":"Alonso Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George L.","family":"Bakris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikhail","family":"Kosiborod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lance","family":"Berman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Mebazaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik S.","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis M.","family":"Ruilope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norman","family":"Stockbridge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aliza","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Wittes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2016.04.127_bb0005","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.semnephrol.2014.04.008","article-title":"Prediction and management of hyperkalemia across the spectrum of chronic kidney disease","volume":"34","author":"Lazich","year":"2014","journal-title":"Semin. Nephrol."},{"key":"10.1016\/j.ijcard.2016.04.127_bb0010","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.amjcard.2012.01.367","article-title":"Predictors of hyperkalemia and death in patients with cardiac and renal disease","volume":"109","author":"Jain","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.04.127_bb0015","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1161\/HYPERTENSIONAHA.108.125252","article-title":"Mechanisms of impaired potassium handling with dual renin\u2013angiotensin\u2013aldosterone blockade in chronic kidney disease","volume":"53","author":"Preston","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2016.04.127_bb0020","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMra035279","article-title":"Managing hyperkalemia caused by inhibitors of the renin\u2013angiotensin\u2013aldosterone system","volume":"351","author":"Palmer","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.04.127_bb0025","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archinte.158.1.26","article-title":"Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?","volume":"158","author":"Reardon","year":"1998","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ijcard.2016.04.127_bb0030","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.2215\/CJN.01150112","article-title":"Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic","volume":"7","author":"Sarafidis","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ijcard.2016.04.127_bb0035","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ijcard.2014.11.004","article-title":"Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries","volume":"177","author":"Rossignol","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.04.127_bb0040","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.ijcard.2014.02.034","article-title":"Incident hyperkalemia may be an independent therapeutic target in low ejection fraction heart failure patients: insights from the HEAAL study","volume":"173","author":"Rossignol","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.04.127_bb0045","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","volume":"7","author":"Rossignol","year":"2014","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.ijcard.2016.04.127_bb0050","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","article-title":"Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study)","volume":"60","author":"Vardeny","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.04.127_bb0055","series-title":"Handbook of Chronic Kidney Disease Management","first-page":"81","article-title":"Restricting dietary sodium and potassium intake: a dietitian's perspective","author":"Greene","year":"2011"},{"key":"10.1016\/j.ijcard.2016.04.127_bb0060","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1681\/ASN.2010010079","article-title":"Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective?","volume":"21","author":"Sterns","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ijcard.2016.04.127_bb0065","series-title":"LLC. Kayexalate Sodium Polystyrene Sulfonate, USP Cation-Exchange Resin Prescribing Information","author":"Sanofi Aventis","year":"2010"},{"key":"10.1016\/j.ijcard.2016.04.127_bb0070","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1525-139X.2007.00312.x","article-title":"Management of hyperkalemia in dialysis patients","volume":"20","author":"Putcha","year":"2007","journal-title":"Semin. Dial."},{"key":"10.1016\/j.ijcard.2016.04.127_bb0075","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1503\/cmaj.100461","article-title":"Management of patients with acute hyperkalemia","volume":"182","author":"Elliott","year":"2010","journal-title":"CMAJ"},{"key":"10.1016\/j.ijcard.2016.04.127_bb0080","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1411487","article-title":"Sodium zirconium cyclosilicate in hyperkalemia","volume":"372","author":"Packham","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.04.127_bb0085","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.04.127_bb0090","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","article-title":"Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial","volume":"32","author":"Pitt","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.04.127_bb0095","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1001\/jama.2014.15688","article-title":"Effect of sodium zirconium cyclosilicate on potassium lowering for 28days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial","volume":"312","author":"Kosiborod","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2016.04.127_bb0100","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3909\/ricm0727","article-title":"Acute and chronic cardiovascular effects of hyperkalemia: new insights into prevention and clinical management","volume":"15","author":"McCullough","year":"2014","journal-title":"Rev. Cardiovasc. Med."},{"key":"10.1016\/j.ijcard.2016.04.127_bb0105","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3909\/ricm0782","article-title":"Novel agents for the prevention and management of hyperkalemia","volume":"16","author":"McCullough","year":"2015","journal-title":"Rev. Cardiovasc. Med."},{"key":"10.1016\/j.ijcard.2016.04.127_bb0110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2217\/fca.11.71","article-title":"PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016","volume":"8","author":"Buysse","year":"2012","journal-title":"Futur. Cardiol."},{"key":"10.1016\/j.ijcard.2016.04.127_bb0115","first-page":"483A","article-title":"RLY5016: A new, effective, non-absorbed, therapeutic polymer to control serum potassium [abstract F-PO1616]","volume":"21","author":"Cope","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ijcard.2016.04.127_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114686","article-title":"Characterization of structure and function of ZS-9, a K+ selective ion trap","volume":"9","author":"Stavros","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ijcard.2016.04.127_bb0125","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","article-title":"Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC heart failure long-term registry","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2016.04.127_bb0130","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","volume":"33","author":"McMurray","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.04.127_bb0135","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.04.127_bb0140","series-title":"USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD","author":"National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases","year":"2013"},{"key":"10.1016\/j.ijcard.2016.04.127_bb0145","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00392-014-0678-2","article-title":"Registry in Germany focusing on level-specific and evidence-based decision finding in the treatment of heart failure: REFLECT-HF","volume":"103","author":"Tebbe","year":"2014","journal-title":"Clin. Res. Cardiol."},{"key":"10.1016\/j.ijcard.2016.04.127_bb0150","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ahj.2007.03.030","article-title":"Improving the use of evidence-based heart failure therapies in the outpatient setting: the IMPROVE HF performance improvement registry","volume":"154","author":"Fonarow","year":"2007","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2016.04.127_bb0155","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/ki.2015.270","article-title":"Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia","volume":"88","author":"Bushinsky","year":"2015","journal-title":"Kidney Int."},{"key":"10.1016\/j.ijcard.2016.04.127_bb0160","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMc1500353","article-title":"Sodium zirconium cyclosilicate for urgent therapy of severe hyperkalemia","volume":"372","author":"Kosiborod","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.04.127_bb0165","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.04.127_bb0170","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2016.04.127_bb0175","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/kisup.2012.67","article-title":"KDIGO clinical practice guideline for the evaluation and Management of Chronic Kidney Disease: chapter 4: other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD","volume":"3","author":"Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.ijcard.2016.04.127_bb0180","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1751-7133.2011.00250.x","article-title":"Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: findings from IMPROVE HF","volume":"18","author":"Gheorghiade","year":"2012","journal-title":"Congest. Heart Fail."},{"key":"10.1016\/j.ijcard.2016.04.127_bb0185","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1001\/jama.2011.1967","article-title":"Serum potassium levels and mortality in acute myocardial infarction","volume":"307","author":"Goyal","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2016.04.127_bb0190","article-title":"Potassium levels and mortality in patients with CKD [abstract]","author":"Collins","year":"2014","journal-title":"J. Am. Soc. Neprhol."},{"key":"10.1016\/j.ijcard.2016.04.127_bb0195","doi-asserted-by":"crossref","DOI":"10.1161\/circ.130.suppl_2.13320","article-title":"Effect of cardiovascular comorbidities on the mortality risk associated with serum potassium [abstract]","volume":"130","author":"Pitt","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.04.127_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/S0735-1097(11)60301-X","article-title":"A multicenter study of dose titration of the oral potassium binder RLY5016 to maintain normal serum potassium in patients with heart failure and chronic kidney disease treated with renin\u2013angiotensin\u2013aldosterone inhibitors and\/or beta blockers [abstract]","volume":"57","author":"Pitt","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.04.127_bb0205","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","article-title":"Effect of patiromer on serum potassium reduction over 52weeks in hyperkalemic patients with diabetic kidney disease: results of the AMETHYST-DN randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2016.04.127_bb0210","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/sim.1963","article-title":"Semi-parametric and non-parametric methods for clinical trials with incomplete data","volume":"24","author":"O'Brien","year":"2005","journal-title":"Stat. Med."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316308270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316308270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T08:49:34Z","timestamp":1655542174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527316308270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":42,"alternative-id":["S0167527316308270"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.04.127","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.04.127","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}